Carrie Cappozzo, MSN, ANP-C, is an adult oncology nurse practitioner for New York Oncology Hematology at Albany Medical Center. She also is a nurse speaker for Amgen Inc., the manufacturer of two of the drugs mentioned in this article. (Submitted December 2002 . Accepted for publication June 30, 2003 Carrie Cappozzo, MSN, ANP-C N eutrophils are the crucial first line of defense against pathogens such as bacteria and fungi (Burg & Pillinger, 2001) . Produced in the bone marrow from blood progenitor cells, neutrophils have a relatively short halflife of about seven to eight hours in the peripheral blood. The high proliferative activity of neutrophil precursors and the high turnover of neutrophils in the periphery make them a target for cytotoxic agents that destroy rapidly proliferating cells in the body. Thus, patients with cancer who are treated with chemotherapy are at high risk for the development of neutropenia.
Neutropenia is a potentially serious side effect of cancer chemotherapy. Because neutrophils are responsible for protecting against infection, the presence of neutropenia may place a patient at serious risk for infection. Febrile neutropenia (temperature > 38.2°C and absolute neutrophil count [ANC] < 500 x 10 6 /l) (Crawford et al., 1991) is a significant risk factor for life-threatening infections that can require hospitalization and treatment with IV antibiotics. The development of infectious complications associated with neutropenia correlates with the depth and duration of the ANC nadir (Bodey, Buckley, Sathe, & Freireich, 1966) . Patients with neutrophil counts below 1.0 x 10 9 /l for one week had a 50% chance of infection and, as the duration of neutropenia increased, the risk of infection neared 100%. These patients had a mortality rate above 50% as long as their counts continued to fall, but
Goal for CE Enrollees:
To enhance nurses' knowledge related to the use of granulocyte-colony-stimulating factor for the prevention of febrile neutropenia in patients with cancer receiving chemotherapy.
Objectives for CE Enrollees:
On completion of this CE, the participant will be able to 1. Describe the effects of granulocyte-colony-stimulating factor on neutrophils. 2. Discuss the factors that increase the risk of febrile neutropenia during chemotherapy. 3. Compare the effects and benefits of filgrastim and pegfilgrastim.
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